Skip to main content

Innovative anti-influenza drugs excluding viral escape

Objective

ANTIFLU is to develop innovative drugs against influenza virus infections based on a novel
concept that precludes the development of viral resistance and ensures efficacy against
upcoming pandemic influenza strains. Viral replication is known to depend on multiple host
factors. Whilst traditional anti-influenza treatments usually target viral factors, ANTIFLU will
aim at drugs interfering with host-response pathways. The concept of drugs targeting human
factors, established in treatment of other diseases, has yet not been sufficiently explored for
treatment of viral infections, although it bears compelling advantages over conventional
antiviral therapies: (i) the avoidance of viral escape mutants and (ii) the broad coverage
against unprecedented viral variants.
ANTIFLU aims to fully exploit this potent approach to fill critical gaps in our current treatment
and prevention options against seasonal and pandemic influenza virus infections. By building
upon an existing panel of potent human targets and firm knowledge derived from FP6 project
RIGHT, an interdisciplinary consortium will pursue the identification and validation of small
molecule ligands and inhibitory RNA molecules effective against influenza infection.
Promising modulators will form the basis to generate lead molecules that will be further
refined to yield clinically applicable therapeutics. Initial preclinical studies will aim at providing
proof of concept in animal models, safety and toxicology profiles. They will allow initiating
complete clinical trials immediately after the phase of FP7 support, thanks to the commitment
already taken by investors from the private sector. The consortium includes several SMEs,
internationally renowned research groups and clinical institutions with extensive experience
in anti-influenza treatment and clinical trials. An already agreed common exploitation model
will provide a smooth route to market and optimal use of the project results.

Field of science

  • /medical and health sciences/health sciences/infectious disease/RNA virus/influenza

Call for proposal

FP7-INFLUENZA-2010
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN EV
Address
Hofgartenstrasse 8
80539 Munich
Germany
Activity type
Other
EU contribution
€ 1 448 954
Administrative Contact
Birgit Gieding (Ms.)

Participants (10)

VICHEM CHEMIE KUTATO KFT
Hungary
EU contribution
€ 621 500,20
Address
Hermann Otto Utca 15
1022 Budapest
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
György Kéri (Prof.)
AARHUS UNIVERSITET
Denmark
EU contribution
€ 548 576
Address
Nordre Ringgade 1
8000 Aarhus C
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Karin Sutherland (Ms.)
LEAD DISCOVERY CENTER GMBH
Germany
EU contribution
€ 1 629 860
Address
Otto Hahn Strasse 15
44227 Dortmund
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Michael Hamacher (Dr.)
INSTITUT PASTEUR
France
EU contribution
€ 38 901
Address
Rue Du Docteur Roux 25-28
75724 Paris Cedex 15
Activity type
Research Organisations
Administrative Contact
Nadia Khelef (Dr.)
ARTTIC
France
EU contribution
€ 344 000
Address
Rue Du Dessous Des Berges 58A
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Bruno Cucinelli (Mr.)
MEDITOX S.R.O
Czechia
EU contribution
€ 8 636
Address
Pod Zamkem 279
28125 Konarovice
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jan Zabsky (Mr.)
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 433 778
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Tatjana Palalic (Ms.)
RiboTask ApS
Denmark
EU contribution
€ 222 232,80
Address
Unsbjergvej 2 A
DK-5220 Odense So
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Jesper Wengel (Dr.)
THE HEBREW UNIVERSITY OF JERUSALEM
Israel
EU contribution
€ 289 560
Address
Edmond J Safra Campus Givat Ram
91904 Jerusalem
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Hani Ben-Yehuda (Ms.)
FORSCHUNGSVERBUND BERLIN EV
Germany
EU contribution
€ 414 000
Address
Rudower Chaussee 17
12489 Berlin
Activity type
Research Organisations
Administrative Contact
Anne Höner (Dr.)